p53 and PCNA expression in advanced colorectal cancer: Response to chemotheraphy and long-term prognosis

International Journal of Cancer

Volumn 69, Issue 6, 1996, Pages 437-441

  Paradiso, Angelo ^a   Rabinovich, Mario ^b   Vallejo, Carlos ^b   Machiavelli, Mario ^b   Romero, Alberto ^b   Perez, Juan ^b   Lacava, Juan ^b   Cuevas, Maria Andrea ^b   Rodriquez, Ricardo ^b   Leone, Bernardo ^b   Sapia, Maria Giovanna ^a   Simone, Giovanni ^a   De Lena, Mario ^a  

^a NATIONAL CANCER INSTITUTE GIOVANNI PAOLO II   (Italy)

^b Grupo Oncologico Cooperative del sur   (Argentina)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLINE; FLUOROURACIL; FOLINIC ACID; METHOTREXATE; PROTEIN P53;

ADULT; ADVANCED CANCER; AGED; ARTICLE; COLORECTAL CANCER; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; INTRAMUSCULAR DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS;

ADULT; AGED; COLORECTAL NEOPLASMS; DISEASE PROGRESSION; DRUG THERAPY, COMBINATION; FEMALE; FLUOROURACIL; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; METHOTREXATE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROLIFERATING CELL NUCLEAR ANTIGEN; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0030453230     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/(sici)1097-0215(19961220)69:6<437::aid-ijc2>3.0.co;2-5     Document Type: Article

References (31)

1. AL-SHENEBER, I.F., SHIBATA, H.R., SAMPALIS, J. and JOTHY, S., Prognostic significance of proliferating-cell-nuclear-antigen expression in colorectal cancer. Cancer, 71, 1954-1959 (1993).
2. AMERICAN JOINT COMMITTEE ON CANCER, Manual for staging of cancer, 3rd ed., p. 7, J.B. Lippincott, Philadelphia (1988).
3. BOSARI, S. and VIALE, G., Cytoplasmic accumulation of p53 protein: an independent prognostic indicator in colorectal adenocarcinomas. J. nat. Cancer Inst., 86, 681-687 (1994).
4. CHABNER, B.A. and MYERS, C.E., Clinical pharmacology of cancer chemotherapy. In: V.T. De Vita Jr., S. Hellman and S.A. Rosenberg (eds.), Cancer, principles and practice of oncology, pp. 348-395, J.B. Lippincott, Philadelphia (1989).
5. CHEN, I.T., AKAMATSU, M., SMITH, M.L., LUNG, F.D.T., DUBA, D., ROLLER, P.P., FORNACE, A.J. and O'CONNOR, P.M., Characterization of p21(Cip1/Waf1) peptide domains required for cyclin E/Cdk2 and PCNA interaction. Oncogene, 12, 595-609 (1996).
6. CHIN, K.V., UEDA, K., PASTRAN, I. and GOTTESMAN, M.M., Modulation of activity of the promoter of the human mdr1 gene by ras and p53. Science, 255, 459-462 (1992).
7. FARANDA, A., COSTA, A., SILVESTRINI, R., QUAGLIOLO, V. and GENNARI, L., S-phase cell fraction in the prognosis of Dukes' stage-D colorectal carcinoma. Cell Proliferation, 27, 561-569 (1994).
8. GOH, H.S., YAO, J. and SMITH, D.R., p53 point mutation and survival in colorectal-cancer patients. Cancer Res., 55, 5217-5221 (1995).
9. GREENBLATT, M.S., BENNETT, W.P., HOLLSTEIN, M. and HARRIS, C.C., Mutations in the p53 tumor-suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res., 54, 4855-4878 (1994).
10. HALL, P.A., LEVISON, D.A., WOODS, A.L., YU, C.C-W., KELLOCK, D.B., WATKINS, J.A., BARNES, D.M., GILLET, C.E., CAMPLEJOHN, R., DOVER, R., WASEEM, N.H. and LANE, D.P., Proliferating-cell-nuclear-antigen (PCNA) immunolocalization in paraffin sections: an index of cell proliferation with evidence of deregulated expression in some neoplasms. J. Pathol., 162, 285-294 (1990).
11. JOHNSTON, P.G., FISHER, E.R., ROCKETTE, H.E., FISHER, B., WOLMARK, N., DRAKE, J.C., CHABNER, B.A. and ALLEGRA, C.J., The role of thymidalate-synthestase expression in prognosis and outcome of adjuvant chemotherapy in patients with rectal cancer. J. clin. Oncol., 12, 2640-2647 (1994).
12. KOECHLI, O., SCHAER, G.N., SEIFERT, B., HORNUNG, R., HALLER, U., EPPENBERGER, U. and MUELLER, H., Mutant p53 protein associated with chemosensitivity in breast-cancer specimens. Lancet, 344, 1647 (1994).
13. KOVAC, D., RUBINIC, M., KRASEVIC, M., KRIZANAC, S., PETROVECKI, M., STIMAC, D. and MELATO, M., Proliferating-cell nuclear antigen (PCNA) as a prognostic factor for colorectal cancer. Anticancer Res., 15, 2301-2302 (1995).
14. LENZ, H.J., DANENBERG, K.D., LEICHMAN, L., LEICHMAN, C. and DANENBERG, P.V., p53 status predicts for response to 5Fu/leucovorin in patients with advanced colon cancer. Proc. Amer. Ass. Cancer Res., 36, 559 (1995).
15. LINDEN, M.D., CHAN, K., KUBUS, J., BROWN, R.D. and ZARBO, R.J., Ki-67 and proliferating-cell-nuclear-antigen tumor proliferative indices in DNA diploid colorectal adenocarcinomas. Correlation with histopathologic characteristics and cell-cycle analysis with two-color DNA flow cytometry. Amer. J. clin. Pathol, 100, 206-212 (1993).
16. LOWE, S.W., BODIS, S., MCCLATCHEY, A., REMINGTON, L., RULEY, H.E., FISHER, D.E., HOUSEMAN, D.E. and JACKS, T., p53 status and the efficacy of cancer therapy in vivo. Science, 266, 807-810 (1994).
17. MACHIAVELLI, M., LEONE, B.A., ROMERO, A., RABINOVICH, M.G., VALLEJO, C.T., BIANCO, A., FEREZ, J.E., RODRIOUEZ, R., CUEVAS, M.A., ALVAREZ, L.A., CHACON, R. and HANNOIS, A., Advanced colorectal carcinoma. Amer. J. clin. Oncol., 14, 211-217 (1991).
18. MAYER, A., TAKIMOTO, M., FRITZ, E., SCHELLANDER, G., KOFLER, K. and LUDWIG, H., The prognostic significance of proliferating-cell nuclear antigen, epidermal-growth-factor receptor and mdr gene expression in colorectal cancer. Cancer, 71, 2454-2460 (1993).
19. MEYER, J.S. and PRIOLEAU, P.G., S-phase fractions of colorectal carcinomas related to pathologic and clinical features. Cancer, 65, 1221-1224 (1981).
20. NAKAE, S., NAKAMURA, T., SHIRONO, J., YOSHIOKA, H., IKEGAWA, R., MIYAMURA, K., KAWASAKI, K., SAITOH, Y. and TABUCHI, Y., Analysis of proliferative activity using anti-proliferating-cell nuclear antigen antibody in colorectal cancer. J. surg. Oncol., 60, 149-153 (1995).
21. NEOPTOLEMOS, J.P., OATES, G.D., NEWBOLD, K.M., ROBSON, A.M., MCCONKEY, C. and POWELL, J., Cyclin/proliferation-cell-nuclear-antigen immunohistochemistry does not improve the prognostic power of Dukes' or Jass' classifications for colorectal cancer. Brit. J. Surg., 82, 184-187 (1995).
22. OZDAMAR, S.O., OZYILKAN, E., OZTKIKAN, O. and KANDEMIR, B., The correlation between p53 tumor-suppressor gene and proliferating-cell-nuclear-antigen expressions in colorectal adenocarcinomas. Pathology Int., 45, 973-975 (1995).
23. 1/S boundary after irradiation. Oncogene, 12, 875-883 (1996).
24. QUINN, C.M. and WRIGHT, N.A., The clinical assessment of proliferation and growth in human tumours: evaluation of methods and applications as prognostic variables. J. Pathol., 160, 93-97 (1990).
25. SCHOTT, A.F., APEL, I.J., NUNEZ, G. and CLARKE, M.F., Bcl-x(L) protects cancer cells from p53-mediated apoptosis. Oncogene, 11, 1389-1395 (1995).
26. SILVESTRINI, R., DAIDONE, M.G., RAO, S. and PILOTTI, S., Immunohistochemical detection of p53 in clinical breast cancers: a look at methodologic approaches. J. nat. Cancer Inst., 87, 1020 (1995).
27. SIMES, R.J. and ZELEN, M., Exploratory data analysis and the use of the hazard function for interpreting survival data: an investigator's prime. J. clin. Oncol., 3, 1418-1431 (1985).
28. TEIXEIRA, C.R., TANAKA, S., HARUMA, K., YOSHIHARA, M., SUMII, K. and KAJIYAMA, G., Proliferating-cell-nuclear-antigen expression at the invasive tumor margin predicts malignant potential of colorectal carcinomas. Cancer, 73, 575-579 (1994).
29. WANI, A.M., Xu, X. and STAMBROOK, P.J., Increased methotrexate resistance and dhfr gene amplification as a consequence of induced Ha-ras expression in NIH 3T3 cells. Cancer Res., 54, 2504-2508 (1994).
30. WILLEIT, C.G., WARLAND, G., HAGAN, M.P., DAY, W.J., COEN, J., SHELLITO, P.C. and COMPTON, C.C., PCNA and mitotic index as a response to pre-operative irradiation therapy of rectal cancer. J. clin. Oncol., 13, 1417-1424 (1995).
31. YAMAGUCHI, A., KUROSAKA, Y., FUSHIDA, S., KANNO, M., YONEMURA, Y., MIWA, K. and MIYAZAKI, I., Expression of p53 protein in colorectal cancer and its relationship to short-term prognosis. Cancer, 70, 2778-2784 (1992).